Advanced breast cancer: Chemotherapy phase III trials that change a standard

Anti-Cancer Drugs

Volumn 18, Issue 7, 2007, Pages 843-859

  Estevez, Laura G ^a,l   Tusquets, Ignasi ^b   Muñoz, Montse ^c   Adrover, Encarnación ^d   Rovira, Pedro Sánchez ^e   Seguí, Miguel Ángel ^f   Rodríguez, César A ^g   Lescure, Álvaro Rodríguez ^h   Ruiz, Manuel ⁱ   Álvarez, Isabel ^j   Mata, Jesús García ^k  

^a Centro Integral Oncologico Clara Campal   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^e Hosp Univ Ciudad de Jaén   (Spain)

^f HOSPITAL DE SABADELL   (Spain)

^g HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^j San Sebastian Oncology Institute   (Spain)

^k Hospital de Orense   (Spain)

^l CIOCC (Programa de Mama)   (Spain)

more..

Author keywords

Advanced breast carcinoma; Chemotherapy; Optimal regimen

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ASTHENIA; BLEEDING; BONE MARROW TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III; FEMALE; HUMANS; MODELS, STATISTICAL; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 34250807080     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3280bad81a     Document Type: Conference Paper

References (27)

1. Jassem J, Pienkowski T, Pluzanska A, Jelic S, Gobunova V, Mrsic-Krmpotic Z, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001; 19:1707-1715.
2. Langley RE, Carmichael J, Jones AL, Cameron DA, Quian W, Uscinska B, et al. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. J Clin Oncol 2005; 23:8322-8330.
3. Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol 2002; 20:3114-3121.
4. Mackey JR, Paterson A, Dirix LY, Dewar J, Chap L, Martin M, et al. Final results of the phase III randomized trial comparing (docetaxel), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer. Presented at the ASCO Annual Meeting; 2002 Abstract number 137.
5. Bonneterre J, Dieras V, Tubiana-Hulin M, Bougnoux P, Bonneterre ME, Delozier T, et al. Phase III multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer 2004; 91:1466-1471.
6. Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003; 21:968-975.
7. Ghersi D, Wilcken N, Simes RJ. A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer 2005; 93:293-301.
8. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812-2823.
9. Chan S, Romieu G, Huober J, Delozier M, Tubiana-Hulin A, Lluch A, et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): Results of a European phase III study. Proc Am Soc Clin Oncol 2005; abstract 501.
10. Albain KS, Nag S, Calderillo-Ruiz G, Jordaan JP, Llombart A, Pluzanska M, et al. Global phase III study of gemcitabine plus paclitaxel versus paclitaxel as frontline therapy for metastatic breast cancer. Proc Am Soc Clin Oncol 2004; abstract 510.
11. Wirk B, Perez E. Role of gemcitabine in breast cancer management: an update. Semin Oncol 2002; 33:S6-S14.
12. Blackstein M, Vogel Cl, Ambinder R, Cowan J, Iglesias J, Melemed A. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 2002; 62:2-8.
13. Brodowicz T, Kostler WJ, Moslinger R, Tomek S, Vaclavik I, Herscovici V, et al. Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast 2000; 9:338-342.
14. Murad AM. Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer. Oncology 2003; 17:26-32.
15. Delfino C, Caccia G, Gonzales LR, Mickiewicz E, Rodger J, Balbiani L, et al. Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer. Oncology 2004; 66:18-23.
16. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, et al. Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: and intergroup trial (E1193). J Clin Oncol 2003; 21:588-592.
17. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83:1797-1805.
18. Reichman BS, Seidman AD, Crown JP, Heelan R, Hakes TB, Lebwohl DE, et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993; 11:1943-1951.
19. Ejlertsen B, Mouridsen HT, Langkjer ST, Andersen J, Sjostrom J, Kjaer M, et al. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). J Clin Oncol 2004; 12:2313-2320.
20. Conte PF, Guameri V, Bruzzi P, Prochilo T, Salvadori B, Bolognesi A, et al. Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial. Cancer 2004; 101:704-712.
21. Alba E, Martín M, Ramos M, Adrover E, Balil A, Jara C, et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Study Group (GEICAM-9903) phase III study. J Clin Oncol 2004; 22:2587-2583.
22. Cresta S, Grasselli G, Mansutti M, Martoni A, Lelli G, Capri G, et al. A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer. Ann Oncol 2004; 15:433-439.
23. Seidman A, Berry D, Cirrincione L, Harris L, Dressler L, Muss H, et al. Phase III study of weekly paclitaxel via 1-hr infusion vs. Standard 3-hr infusion every third week in the treatment of metastatic breast cancer, with trastuzumab for HER2+MBC and randomized for trastuzumab for HER2 normal. CALGB 9840. Presented at the 2004 ASCO Annual Meeting, Abstract number 512.
24. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 2004; 22:2061-2068.
25. Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, et al. Randomized Phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23:5542-5551.
26. Miller KD. E2100: a randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab for metastatic breast cancer. Clin Breast Cancer 2003; 3:421-422.
27. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001; 22:4216-4223.